###### Key questions

What is already known about this subject?
=========================================

-   Exercise and physical activity is known to be beneficial by improving the physical and emotional well-being.

-   More specifically, exercise programmes during and after treatment improved side effects (eg, fatigue) and seemed to decrease depression symptoms.

-   The results from different types and dose of exercise in depressive symptoms among breast cancer survivors are modest.

What does this study add?
=========================

-   This study adds more information about the optimal type of exercise intervention that breast cancer survivors should have in order to decrease depressive symptoms.

-   More specifically, it becomes clear how much time and duration of each different type of exercise is needed in order to have positive effects in depressive symptoms.

-   Moreover, this study gives evidence about the positive effects of exercise in patients under treatment.

How might this impact on clinical practice?
===========================================

From clinical practice, it might be worth offering specific exercise interventions when patients are under treatment or starting as early as possible after diagnosis to help survivors go through one of the most difficult phases of their life.

Introduction {#s1}
============

Breast cancer remains by far the most common cancer affecting women worldwide, with an estimated 25% incidence rate among all female cancers.[@R1] This disturbing figure is somehow mitigated by the increasing survival rates of patients with breast cancer, which are attributed mostly to improvements in diagnosis (eg, early detection) and treatment.[@R1] In fact, the 5-year, 10-year and 15-year relative survival rates for breast cancer of 80%--95%, 83% and 78%, respectively, are of the highest 5-year survival rates among female malignancies.[@R1] Thus, breast cancer is nowadays considered a treatable chronic disease, rather than a fatal one. This new perspective has led to a new era in oncology treatment, namely, survivorship, which refers to those who are cancer free for at least 5 years after diagnosis.[@R2] Specifically, a breast cancer survivor is anyone who has been diagnosed with the disease from the point of diagnosis to the end of life.[@R5] Survivorship encompasses all phases during cancer, from active treatment to recovery, in which the transition from being a 'patient' with breast cancer to 'survivor' takes place through living after recovery, including those who are symptom free or stable and finally up to the phase where advanced cancer, recurrence and death may occur.[@R4]

Inevitably, at some point right after diagnosis or throughout their survivorship, most breast cancer survivors will encounter different physical and psychological side effects related to cancer and its treatments.[@R7] With the well-documented extended longevity of breast cancer survivors, the challenge for the medical community has shifted from merely treating the disease to acknowledging and successfully managing these symptoms and side effects in a way that will improve patients' overall quality of life and provide them with emotional care and support during survivorship.[@R8]

Depressive mood is a negative psychological outcome usually reported by breast cancer survivors both during and after treatment, with prevalence ranging between 1.5% and 46%.[@R9] Symptoms are more intense during diagnosis and active treatment, and prevalence is twice as high compared with that found in the general population.[@R10] Despite a gradual reduction in depressive rates throughout survivorship, some women remain chronically with depressive symptoms or become depressed after treatment, especially women with disease recurrence for whom levels of depression mood increase sharply.[@R11] Moreover, depression mood may cause poor adherence to treatment plans and even reduce the chance of survival in women with breast cancer,[@R7] which, if left untreated, can increase the risk for physiological comorbidities.[@R13] These associations underline the paramount importance of applying effective treatments to reduce depressive symptoms in breast cancer survivors.

Previous evidence suggests that physical activity is a non-pharmacological, safe, feasible and relatively low-cost alternative to depression mood management among women with breast cancer.[@R7] Performing any form of regular exercise and maintaining an active lifestyle in general plays an important role for breast cancers survivors. It helps them to reduce specific side effects of treatment, for example, weakness and depressive symptoms, and it has been shown to increase survival rates and decrease the risk of cancer reappearance.[@R14] In fact, major health organisations recommend that cancer survivors should have at least 150 min of moderate-intensity or 75 min of high-intensity exercise combined with a minimum of two strengthening exercise sessions on a weekly basis.[@R6]

Most of the available research findings suggest that physical activity is an effective way for depression management in breast cancer survivors, despite the fact that several limitations and methodological weaknesses of relevant studies have been consistently reported. These include, but are not limited to, small sample sizes, studies mostly involving white participants, poor reporting of adherence and differences in socioeconomic status, failure to follow intent-to-treat analysis and, most importantly, low baseline depression levels as well as depression not being the primary study outcome. Most of the included studies in the aforementioned reviews and meta-analyses have been published before 2012, and in some cases, review articles involving breast cancer survivors are overlapping. Yet to our knowledge, the effect of exercise in depressive symptoms among breast cancer survivors has not been critically evaluated due to non-uniform reporting of modes, intensity, frequency and duration of exercise interventions. Because of this, many systematic reviews have suggested that the optimal exercise programme and programme components need to be further explored.[@R7]

Therefore, the purpose of this literature review paper is to present the most recent studies dealing with the effects of physical activity and exercise on depression mood experienced by breast cancer survivors. Moreover, we aim to clarify if scientists have reached a consensus about the most beneficial physical activity and exercise intervention in terms of type and duration for breast cancer survivors during and after treatment. It is hoped that the information provided will be valuable for doctors, psychologists, physiologists and also for the survivors themselves.

Methods {#s2}
=======

Literature search {#s2a}
-----------------

We searched PubMed, Elsevier and Google Scholar up to November 2016. The reference list of the retrieved articles was examined for cross references. The search included the use of terms such as breast cancer, depression, depressed mood, physical activity, exercise, treatment, psychological effects or a combination of these terms. For the purposes of this study, we used the term 'depressed mood', which is a symptom of depression,[@R9] as a synonym to depressive symptoms in order to avoid the parallelism with the clinical disorder. Moreover, authors have used the terms 'exercise' and 'physical activity' alternatively. While some studies have used exercise interventions where the main goal was fitness improvement and required access to facilities or equipment, other studies referred to different forms of physical exertion of moderate physical activity, such as home-based walking regimes or even occupational and household activities.[@R14]

Inclusion criteria {#s2b}
------------------

Studies included in this review met the following criteria: (a) were written in English; (b) were published in 2011 and beyond (for secondary studies from the same research team, an original article had to be published in 2008 and afterwards; the year 2011 was chosen because there was a gap in literature findings in meta-analysis for the effect of exercise in depression in breast cancer survivors); (c) participants were adult women diagnosed with breast cancer based on mammography and biopsy; (d) included an intervention programme involving physical activity; (e) used a randomised controlled trial (experimental) design; and (f) results for depression outcomes.

Exclusion criteria {#s2c}
------------------

Studies were excluded mainly due to: (a) inclusion of other types of cancer survivors; (b) inability to have access to the entire article; and (c) publication date before 2011 or before 2008 for primary or secondary studies.

Data extraction {#s2d}
---------------

Relevant data were extracted by an excel template including: (1) characteristics of the study and participants (first author, year of publication, mean age, sample size; (2) characteristics of exercise intervention (type, total duration, intensity, frequency, session duration); and (3) outcomes of intervention on depressive symptoms.

Methodological quality assessment {#s2e}
---------------------------------

The methodological quality of the studies was assessed according to PEDro criteria list,[@R15] which is a set of 10 criteria for quality assessment of randomised control trials. Each item was scored as yes (×) or no (−).

Outcomes {#s2f}
--------

The primary outcome was the standardised mean difference in depressed mood measured by total scores on the Hospital Anxiety and Depression Scale (HADS)[@R20] or by the Center for Epidemiologic Studies-Depression (CES-D) questionnaire[@R21] or by the Beck Depression Inventory (BDI-II)[@R22] or scores of Profile of Mood State (POMS)[@R23] ([table 1](#T1){ref-type="table"}). Secondary outcome measures included type and duration of exercise and depressed mood. Additionally, outcomes from the effect of exercise interventions in depressive symptoms in patients during treatment and post-treatment were measured.

###### 

Depression assessments and results

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Primary outcome                                                                                                    Measure\                                                  Baseline depression score, mean (SD) Intervention(s)/control              Post-treatment and follow-up depression scores and differences from baseline, mean (SD) Intervention(s)/control
                                                                                                                                                          tool and scoring                                                                                                                    
  ------------------------------------ ------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------- ------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  Bower *et al*[@R29]                  Fatigue                                                                                                            BDI-II (0--63; higher is worse)                           15.5 (7.5)/14.3 (7.5)                                                     PT: 12 weeks: 7.7 (5.8)/11.6 (7.1); groups differed significantly\
                                                                                                                                                                                                                                                                                              50.3%/18.8% reduction in symptoms\
                                                                                                                                                                                                                                                                                              FU: 3 months: 9.9 (8.0)/10.5 (7.9); groups did not significantly differ 36.1%/32.2% reduction in symptoms

  Cantarero-Villanueva *et al*[@R38]   Fatigue                                                                                                            POMS (0--60; higher is worse)                             52.39 (12.14)/52.42 (11.01)                                               PT: 8 weeks: 47.15 (9.34)/52.40 (10.91); groups differed significantly\
                                                                                                                                                                                                                                                                                              10%/0.04% reduction in symptoms\
                                                                                                                                                                                                                                                                                              FU: 6 months: 48.17 (8.94)/55.30 (12.12); groups differed significantly\
                                                                                                                                                                                                                                                                                              8% reduction/5.5% increase in symptoms

  Naumann *et al*[@R34]                Physiological function, QoL, depression, fatigue                                                                   BDI (0--63; higher is worse)                              Ex: 11.7 (2.71)/ExC: 15.0 (3.03)/C: 15.3 (3.10)/8.9/1 (2.89)†             PT: 8 weeks†: Ex: 8.1 (1.31)/ExC: 11.0 (1.48)/C: 15.0 (1.51)/10.91 (1.44); Ex and ExC intervention groups differed significantly with control group\
                                                                                                                                                                                                                                                                                              30.7%/26.6%/2% reduction/22.5% increase in symptoms

  Cantarero-Villanueva *et al*[@R33]   Fatigue                                                                                                            POMS (0--60; higher is worse)                             48.55 (9.31)/52.25 (11.55)                                                PT: 8 weeks: 45.58 (9.68)/53.71 (11.60); groups differed significantly\
                                                                                                                                                                                                                                                                                              6.1% reduction/2.8% increase in symptoms\
                                                                                                                                                                                                                                                                                              FU: 6 months: 46.03 (9.01)/52.68 (11.84); groups differed significantly\
                                                                                                                                                                                                                                                                                              5.2% reduction/0.8% increase in symptoms

  Ergun *et al*[@R42]                  Cytokine levels                                                                                                    BDI (0--63; higher is worse)                              Supervised: 7.75 (6.69)/home based: 9.05 (8.18)/educational: 7.5 (7.95)   PT: 12 weeks: supervised: 4.70 (4.10)/home based: 8.88 (10.48)/educational: 5.15 (5.18); groups did not significantly differ\
                                                                                                                                                                                                                                                                                              39.4%/1.9%/31.3% reduction in symptoms

  Spahn *et al*[@R35]                  Fatigue                                                                                                            HADS (0--21; higher is worse)                             5.3 (3.6)/6.4 (3.4)                                                       PT: 10 weeks: 3.8 (3.7)/5.7 (3.4); groups did not significantly differ 28.3%/10.9% reduction in symptoms\
                                                                                                                                                                                                                                                                                              FU: 3 months: 5.3 (4.3)/6.0 (4.3); groups did not significantly differ 0%/6.3% reduction in symptoms

  Chandwani *et al*[@R36]              Physical and mental components of QoL                                                                              CES-D (0--60; cut-off score ≥16)                          Yoga: 15.4 (1.5)/stretching: 11.7 (0.8)/wait list: 15.1 (1.4)             Groups did not significantly differ at any of the four time points\
                                                                                                                                                                                                                                                                                              PT: 6 week: 17.3 (1.4)/17.8 (1.1)/15.8 (1.4)\
                                                                                                                                                                                                                                                                                              12.3%/52.1%/4.6%increase in symptoms\
                                                                                                                                                                                                                                                                                              FU: 1 month: 13.1 (1.7)/11.6 (1.4)/12.3 (1.3)\
                                                                                                                                                                                                                                                                                              14.9%/0.8%/18.5% reduction in symptoms\
                                                                                                                                                                                                                                                                                              FU: 3 months: 13.9 (1.7)/9.6 (1.4)/12.9 (1.6)\
                                                                                                                                                                                                                                                                                              9.7%/17.9%/14.6% reduction in symptoms\
                                                                                                                                                                                                                                                                                              FU: 6 months: 13.9 (1.8)/10.4 (1.4)/11.5 (1.3)\
                                                                                                                                                                                                                                                                                              9.7%/11.1%/23.8% reduction in symptoms

  Courneya *et al*[@R39]               Depression                                                                                                         CES-D short form (0--30; cut-off score ≥8)                High: 6.3 (5.1)/\                                                         Groups did not significantly differ at any of three time points (1/3 and 2/3 through chemotherapy, postchemotherapy)\
                                                                                                                                                                                                                    combined: 5.8 (5.0)/\                                                     FU: high: 5.9 (0.33)/combined: 6.4 (0.32)/standard: 6.8 (0.33)‡\
                                                                                                                                                                                                                    standard: 5.6 (3.9)                                                       6.3% reduction/10.3%/21.4% increase in symptoms

  Saxton *et al*[@R32]                 NS indices of psychological health status (depression/perceived stress, HPA axis regulation and immune function)   BDI-II (0--63; higher is worse)                           11.3 (7.6)/10.2 (5.5)                                                     FU: 6 months: 5.1 (4.9)×(6.1 point reduction clinically meaningful)/\
                                                                                                                                                                                                                                                                                              7.9 (6.0); groups differed significantly\
                                                                                                                                                                                                                                                                                              54.9%/22.5% reduction in symptoms

  Steindorf *et al*[@R30]              Fatigue                                                                                                            CES-D (linearly rescaled to 0--100, cut-off score \>38)   26(17)/28(17)                                                             PT: 12 weeks: 25 (18)/25 (17); groups did not significantly differ\
                                                                                                                                                                                                                                                                                              3.8% reduction/10.7% increase in symptoms

  Rock *et al*[@R6]                    QoL (vitality and functioning)                                                                                     CES-D (0--60; cut-off score ≥16)                          9.9 (0.50)/9.7 (0.50)                                                     FU: 6 months: 11.4 (0.44)/10.6 (0.44); groups did not significantly differ\
                                                                                                                                                                                                                                                                                              15.1%/9.3% increase in symptoms\
                                                                                                                                                                                                                                                                                              12 months: 11.9 (0.45)/10.9 (0.47); groups did not significantly differ\
                                                                                                                                                                                                                                                                                              20.2%/12.4% increase in symptoms\
                                                                                                                                                                                                                                                                                              24 months: 11.8 (0.47)/9.9 (0.47); groups differed significantly in favour of control group\
                                                                                                                                                                                                                                                                                              19.2%/2% increase in symptoms

  Schmidt *et al*[@R41]                Fatigue                                                                                                            CES-D (linearly rescaled to 0--100, cut-off score \>38)   20.3 (10.7)/20.3 (9.9)                                                    PT: 12 weeks: 20.4 (12.8)/21.1 (13.2); groups did not significantly differ\
                                                                                                                                                                                                                                                                                              0.5% reduction/3.9% increase in symptoms

  Travier *et al*[@R37]                Fatigue                                                                                                            HADS (20-item Dutch version)                              2.5 (3.1)/2.4 (2.7)                                                       Scores NR. Groups did not significantly differ at PT (18 weeks) and FU (36 months)

  Gokal *et al*[@R40]                  Psychosocial measures (depression included)                                                                        HADS (0--21; higher is worse)/\                           HADS: 5.52 (3.79)/\                                                       PT: 12 weeks: HADS: 4.44 (3.37)/6.16 (2.21); groups did not significantly differ 19.6%/7.8% reduction in symptoms\
                                                                                                                                                          POMS-SF                                                   6.68 (4.00)\                                                              POMS-SF: 1.68 (2.01)/6.44 (4.99); groups differed significantly\
                                                                                                                                                                                                                    POMS-SF: 4.92 (5.31)/6.68 (5.72)                                          65.8%/3.6% reduction in symptoms
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Significant reduction in depression score from baseline (P\<0.05).

†Adjusted mean (SE).

‡Average adjusted mean score (SE) for the three time points.

BDI-II, Beck Depression Inventory; CES-D, for Epidemiologic Studies-Depression; FU, Follow up; HADS, Hospital Anxiety and Depression Scale; HPA, Hippocampus; POMS, Profile of Mood State; PT, Post Treatment; QoL, quality of life; NS, Not Stated.

Statistical analysis {#s2g}
--------------------

Data were pooled for all studies examined: (1) the effect of exercise in general, (2) the effect of the different types of intervention on depressive symptoms, (3) the effect of the duration of intervention and (4) the effect of the exercise intervention during and after treatment. More specifically, we performed effect size analysis in the studies that used low exercise duration within a week period (≤135 min/week) as to compare it with an effect size of the studies that used high exercise duration within a week period (≥135 min/week). Furthermore, we performed effect size analysis in the studies that used a sufficient duration of the overall exercise programme (≤12 weeks) as to compare it with an effect size of the studies that used high duration of the overall exercise programme (≥12 weeks). The separation of the studies regarding both the exercise duration within a week period and the exercise duration of the overall exercise programme was made with the method of 50th percentile. For studies that included more than one follow-up comments, the last follow-up was used in order to conclude the effect of exercise on depression. For the intervention group, studies were classified according to the exercise moderators in four types: aerobic (eg, cardiovascular exercise, treadmill running and walking), resistance (muscle strength training), aerobic and resistance and yoga.

Effect sizes were computing using the Comprehensive Meta Analysis V.2.0.[@R24] Hedges' g was used as a measure of the effect size. The standardised mean difference between the exercise and the control groups divided by the pooled SD was used to compute the effect size in each study. An effect size ≤0.2 reflects a negligible difference, between ≥0.2 and ≤0.5 a small difference, between ≥0.5 and ≤0.8 a moderate difference and ≥0.8 a large difference.[@R25]

Prior to analysis, data were assessed for publication bias using the methods of Begg[@R26] and Egger *et al*.[@R27] Statistical heterogeneity among studies was measured by Q-statistic together with I^2^ test.

Results {#s3}
=======

Study selection {#s3a}
---------------

A total of 432 were retrieved from the database. A total number of 15 relevant systematic reviews and meta-analyses were also examined from the reference list in order to identify additional studies. Using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines,[@R28] 14 randomised controlled trials were finally included, while 107 articles were excluded in which the design of the study failed to meet the inclusion criteria ([figure 1](#F1){ref-type="fig"}).

![Flow diagram of study selection. RCT, randomised controlled trial.](esmoopen-2017-000271f01){#F1}

Methodological quality of included studies {#s3b}
------------------------------------------

We assessed 14 randomised control trials according to the PEDro criteria list. In all 14 studies, 2 studies met eight criteria,[@R29] 9 studies met seven criteria,[@R31] 2 studies met six criteria[@R33] and 1 of the them met five criteria.[@R40] The mean PEDro score of the studies was 6.1±2, indicating high quality[@R19] ([table 2](#T2){ref-type="table"}).

###### 

Methodological quality assessment

  Study                                Random allocation   Concealed allocation   Baseline similarity   Blinding of participants   Blinding of therapists   Blinding of assessors   Measures of key outcomes more than 85% of participants   Intention-to-treat analysis   Between-group statistical comparisons   Point measures and measures of variability   Total
  ------------------------------------ ------------------- ---------------------- --------------------- -------------------------- ------------------------ ----------------------- -------------------------------------------------------- ----------------------------- --------------------------------------- -------------------------------------------- -------
  Bower *et al*[@R29]                  **×**               **×**                  **×**                 **×**                      **−**                    **×**                   **--**                                                   **×**                         **×**                                   **×**                                        **8**
  Cantarero-Villanueva *et al*[@R38]   **×**               **\_-**                **×**                 **×**                      **--**                   **×**                   **--**                                                   **--**                        **×**                                   **×**                                        **6**
  Naumann *et al*[@R34]                **×**               **--**                 **×**                 **×**                      **--**                   **--**                  **×**                                                    **×**                         **×**                                   **×**                                        **7**
  Cantarero-Villanueva *et al*[@R33]   **×**               **×**                  **×**                 **×**                      **--**                   **×**                   **--**                                                   **--**                        **×**                                   **×**                                        **7**
  Ergun *et al*[@R42]                  **×**               **--**                 **×**                 **×**                      **--**                   **×**                   **--**                                                   **--**                        **×**                                   **×**                                        **6**
  Spahn *et al*[@R35]                  **×**               **--**                 **×**                 **×**                      **--**                   **×**                   **×**                                                    **--**                        **×**                                   **×**                                        **7**
  Chandwani *et al*[@R36]              **×**               **--**                 **×**                 **×**                      **--**                   **×**                   **×**                                                    **--**                        **×**                                   **×**                                        **7**
  Courneya *et al*[@R39]               **×**               **×**                  **×**                 **×**                      **--**                   **×**                   **--**                                                   **--**                        **×**                                   **×**                                        **7**
  Saxton *et al*[@R32]                 **×**               **×**                  **×**                 **×**                      **--**                   **--**                  **--**                                                   **×**                         **×**                                   **×**                                        **7**
  Steindorf *et al*[@R30]              **×**               **×**                  **×**                 **--**                     **--**                   **×**                   **×**                                                    **×**                         **×**                                   **×**                                        **8**
  Rock *et al*[@R6]                    **×**               **×**                  **×**                 **×**                      **--**                   **×**                   **--**                                                   **--**                        **×**                                   **×**                                        **7**
  Schmidt *et al*[@R41]                **×**               **--**                 **×**                 **×**                      **--**                   **--**                  **×**                                                    **--**                        **×**                                   **×**                                        **6**
  Travier *et al*[@R37]                **×**               **×**                  **×**                 **--**                     **--**                   **×**                   **--**                                                   **×**                         **×**                                   **×**                                        **7**
  Gokal *et al*[@R40]                  **×**               **--**                 **×**                 **×**                      **--**                   **--**                  **--**                                                   **--**                        **×**                                   **×**                                        **5**

Reviewed studies and breast cancer survivor characteristics {#s3c}
-----------------------------------------------------------

In total, 14 studies met all inclusion criteria and are presented in this review. All studies were published between 2011 and 2016, and the actual year of trial completion for more than half of them was after 2011. Six of them were conducted in North America (USA n=4 and Canada n=2) and eight in Europe (Germany and Spain n=2 each, United Kingdom n=2, Turkey and the Netherlands n=1 each). Sample sizes ranged from 10[@R34] to 300[@R31] participants, with a mean of 60.7, while nine studies recruited less than 100 breast cancer survivors. Control groups included participants assigned to usual care, health education, wait list, relaxation and stretching comparable with the interventions applied to exercise groups. Ten and 8 out of the 14 studies reported on adherence and adverse events related to exercise intervention, respectively. Five studies reported on participant's ethnicity, 10 on marital status and 7 on menopausal state. Data on income (n=3), education (n=9) and occupation (n=7) were also reported, with two studies providing data on all three variables of women's socioeconomic status.

For assessment of participants' depression levels, studies used the CES-D questionnaire (n=5), the BDI (n=4), the HADS (n=3) and the POMS (n=2). Depression was the sole primary outcome measure in only one study,[@R39] while in three more studies,[@R32] depression was included either as primary or not as psychosocial/psychological outcome. In eight studies, primary outcomes included fatigue,[@R29] and in three quality of life[@R31] and behaviour change, leisure time physical activity and cytokine levels (n=1 each).

The median age of the included breast cancer survivors was 52 years. In all studies, women had been diagnosed with 0--IIIc stage breast cancer. When reported, the majority of participants were postmenopausal (75.2%), white (73.5%), married (68.9%), employed (67.9%) and well educated (59.1%). Participants had completed cancer treatment prior to physical activity intervention in eight studies,[@R29] while in six studies[@R30] participants were undergoing adjuvant therapy, that is, chemotherapy and/or radiation therapy during exercise intervention ([table 3](#T3){ref-type="table"}).

###### 

Sample and breast cancer characteristics

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study,\                                      Actual years of trial   Age of\                   Sample size (N)\    Race/ethnicity %   Body mass index\                         Marital status (married %)   Employment\    Income status (high %)   Education\   Cancer\   Time of measurement (since diagnosis or treatment) at baseline or timing       Menopausal status\
  first author,\                                                       participants (years),\    Intervention(s)/\                      (kg/m^2^), mean (SD) Intervention(s)/\                                status\* (%)                            (\>high\     stage                                                                                    (postmenopausal %)
  year,\                                                               mean\                     control                                control                                                                                                       school %)                                                                                             
  country                                                              (SD)\                                                                                                                                                                                                                                                                                
                                                                       Intervention\                                                                                                                                                                                                                                                                        
                                                                       (s)/control                                                                                                                                                                                                                                                                          
  -------------------------------------------- ----------------------- ------------------------- ------------------- ------------------ ---------------------------------------- ---------------------------- -------------- ------------------------ ------------ --------- ------------------------------------------------------------------------------ ----------------------------
  Randomised control trials during treatment                                                                                                                                                                                                                                                                                                                

  Schmidt (2015)[@R41] Germany                 2010--2013              52.2 (9.9)/\              52/49               NR                 25.7 (4.6)/\                             NR                           NR             NR                       NR           0--III    During adjuvant chemotherapy                                                   NR
                                                                       53.3 (10.2)                                                      26.3 (4.9)                                                                                                                                                                                                          

  Courneya (2014)[@R39] Canada                 2008--2011              50.1 (8.8)/50.5 (9.4)/\   101/104/96          White 84.7         25.2 (4.5)/\                             64.5                         41.9           54.3                     64.8         0--IIIC   Initiating adjuvant chemotherapy                                               NR
                                                                       49.2 (8.4)                                                       28.2 (6.5)/\                                                                                                                                                                                                        
                                                                                                                                        26.0 (4.9)                                                                                                                                                                                                          

  Steindorf (2014),[@R30] Germany              2011--2013              55.2 (9.5)/\              80/80               NR                 26.9 (5.4)/\                             NR                           NR             NR                       NR           0--III    During radiotherapy                                                            NR
                                                                       56.4 (8.7)                                                       27.6 (4.8)                                                                                                                                                                                                          

  Chandwani (2014)[@R36]\                      2006--2009              52.38 (1.35)/\            53/56/54            White 64.7         NR                                       67.5                         57             55.7                     74.3         0--III    Undergoing radiotherapy                                                        NR
  USA                                                                  51.14 (1.32)/\                                                                                                                                                                                                                                                                       
                                                                       52.11 (1.34)                                                                                                                                                                                                                                                                         

  Travier (2015),[@R37] Netherlands            2010--2013              49.7 (8.2)/\              102/102             NR                 25.8 (4.4)/\                             76                           NR             NR                       40.7         0--III    Within 6 weeks of diagnosis during chemotherapy                                38.2
                                                                       49.5 (7.9)                                                       26.6 (5.2)                                                                                                                                                                                                          

  Gokal (2016)[@R40] UK                        2012--2013              52.08 (11.7)/\            25/25               NR                 27.20 (4.82)/\                           76                           86             NR                       22           0--III    During chemotherapy                                                            62
                                                                       52.36 (8.9)                                                      28.25 (5.83)                                                                                                                                                                                                        

  Randomised control trials after treatment                                                                                                                                                                                                                                                                                                                 

  Cantarero-Villanueva (2012)[@R38] Spain      2009--2010              49(9)/48(9)               38/40               NR                 NR                                       61                           58.2           NR                       43.2         0--IIIA   Finished coadjuvant treatment except hormone therapy                           65.6

  Naumann[@R34] (2012) USA                     NR                      49.0 (10.0)/\             11/12/10            NR                 27.3 (1.50)/\                            NR                           NR             NR                       NR           0--III    Within 12 months of treatment completion except hormone therapy                NR
                                                                       49.0 (8.2)/\                                                     27.5 (1.49)/\                                                                                                                                                                                                       
                                                                       51.8 (11.5)                                                      27.4(1.49)^c^                                                                                                                                                                                                       

  Bower[@R29] (2012) USA                       2007--2010              54.4 (5.7)/53.3 (4.9)     16/15               White 87           24 (2.5)/25.3 (3.4)                      74                           NR             83.8                     58           0--II     At least 6 months post-treatment                                               100

  Cantarero-Villanueva[@R33] (2013)\           2009--2010              49 (7)/47(8)              34/34               NR                 NR                                       63                           57.4           NR                       44.2         0--IIIA   Finished oncology treatment except hormone therapy in the previous 18 months   72.1
  Spain                                                                                                                                                                                                                                                                                                                                                     

  Spahn[@R35] (2013) Germany                   NR                      58.1 (8.5)/\              32/32               NR                 26.6 (4.1)/\                             NR                           NR             NR                       NR           I--III    Completed treatment except hormone therapy at least 3 months before            NR (menopausal transition)
                                                                       55.3 (11.4)                                                      26.9 (4.3)                                                                                                                                                                                                          

  Ergun[@R42] (2013)\                          NR                      49.65 (8.25)/\            20/20/20            NR                 26.55 (4.40)/\                           77                           47             NR                       38           0--III    Completed treatment                                                            100
  Turkey                                                               55.05 (6.85)/\                                                   28.64 (5.15)/\                                                                                                                                                                                                      
                                                                       50.30 (10.37                                                     50.30 (10.37)                                                                                                                                                                                                       

  Saxton[@R32] (2014), UK                      NR                      55.8 (10)/\               44/41               White 99           29.7 (3.5)/\                             68.2                         NR             NR                       NR           0--III    Completed treatment 3--18 months previously                                    NR
                                                                       55.3 (8.8)                                                       31.1 (5.7)                                                                                                                                                                                                          

  Rock[@R6] (2015), USA                        2010--2012              56.4 (9.53)/\             344/348             White 79           \>25 for both groups                     66.9                         91.6           NR                       85.7         I--III    Completed treatment                                                            87.4
                                                                       56.0 (9.47)                                                                                                                                                                                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Employed and retired and on sick leave.

**†**Indicates original articles describing details about participant characteristics and/or intervention design.

‡Adjusted mean (SE).

Exercise intervention characteristics {#s3d}
-------------------------------------

In 11 studies, the length of the interventions ranged from 6 (shortest[@R36]) to 12 weeks and from 16 to 52 weeks (longest)[@R32] in the remaining 3 studies. The reported exercise frequency was 2--3 sessions per week for the majority of the studies, while duration varied from 30 to 90 min per session. Consequently, weekly exercise duration ranged from 90 to 270 min. Exercise intensity also varied widely, from low to vigorous (high), with moderate intensity being most frequently reported. Many studies reported that intensity was determined and adjusted/prescribed following the American Cancer Society (ACS), the American Heart Association (AHA) and the American College of Sports Medicine (ACSM) recommendations and guidelines.

Types of exercise used in interventions solely or in combination included aerobic, resistance, aerobic and resistance and yoga exercises. More specifically, two studies involved a yoga intervention,[@R29] three[@R35] only aerobic, two studies[@R30] applied resistance intervention programmes and six a combination of aerobic and resistance training programme.[@R32] When reported, activities for aerobic exercises included walking and/or the use of treadmill, elliptical, cross-trainer, cycling/rowing ergometer, various movements in water, fast arm movements and whole-body aerobic and step exercises. For resistance exercise, whole-body activities with or without the use of equipment (elastic/resistance/Thera bands, machines, dumbbells, stability balls, etc) were used. Of the 14 interventions, 12 involved supervised exercise sessions, while 2 included only home-based sessions. All studies had over 80% up to as high as 99% retention rates, while adherence rates, when reported, varied from 70% to 92.7%, and the majority of the studies observed no adverse events related to exercise (data not shown). [Table 4](#T4){ref-type="table"} summarises exercise intervention characteristics of the reviewed studies.

###### 

Intervention characteristics

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Intervention group(s) components                                                                                                                  Control group(s)\                                              Exercise mode, supervised versus home based in intervention group(s)    Exercise activity                                                                                                         Length (weeks)   Frequency (sessions/week)   Duration/session\                               Intensity
                                                                                                                                                                                         treatment                                                                                                                                                                                                                                                                                                     (minutes)                                       
  ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ---------------- --------------------------- ----------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Bower *et al*[@R29]                  Lyengar yoga                                                                                                                                      Health education classes                                       Yoga, supervised                                                        Yoga                                                                                                                      12               2                           90                                              Low

  Cantarero-Villanueva *et al*[@R38]   Multimodal physical training and recovery procedures                                                                                              UC                                                             AE, RE, stretching, massage, supervised                                 AE: unspecific work progressing to fast working with arms movement\                                                       8                3                           90                                              AE: moderate (ACSM/AHA rec)\
                                                                                                                                                                                                                                                                                                                                RE: Core stability exercises: soft-ball, fit-ball, elastic band                                                                                                                                                        RE: 75% of maximum load, whole-body progressive 2--3 sets of 10--15 reps

  Naumann *et al*[@R34]                Multimodal exercise training/exercise and counselling/counselling programme                                                                       UC                                                             AE, RE, patient-specific rehab core training, flexibility, supervised   NR                                                                                                                        8                3                           45--60                                          Moderate (ACSM rec)

  Cantarero-Villanueva *et al*[@R33]   Deep-water aquatic exercise programme                                                                                                             UC                                                             AE, RE, mobility, stretching, supervised                                AE: different horizontal movements RE: exercises progressively with equipment (pool noodles, pull buoy, swimming board)   8                3                           60:10 warm up, 40 (5--15 AE+RE), 10 cool down   AE: moderate (ACSM/AHA rec)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       RE: whole-body progressive 2--3 sets of 10--15 reps BRPES (ACSM/AHA rec)

  Ergun *et al*[@R42]                  Supervised exercise/home-based exercise                                                                                                           Education programme                                            AE, RE, stretching, relaxation, supervised/AE, home based               AE: brisk walking, RE: Thera band whole-body, semisquats                                                                  12               3                           75: 45: AE+RE (10 warm up), 30 Walking/30       RE: moderate, AE: moderate

  Spahn *et al*[@R35]                  Multimodal mind--body programme (nutrition counselling, relaxation, physical exercise, stress reduction, cognitive restructuring, hydrotherapy)   Home-based walking intervention                                AE, supervised (weeks 1, 3, 10) and home based                          Walking                                                                                                                   10               3                           30                                              HR: 180− (chronological age±10) bpm

  Chandwani *et al*[@R36]              Yoga                                                                                                                                              Stretching/wait list                                           Yoga, supervised                                                        Yoga                                                                                                                      6                3                           60                                              Low

  Courneya *et al*[@R39]               High AE programme/combined AE+RE programme                                                                                                        Standard AE programme (25--30 min vigorous ACSM and ACS rec)   AE, RE, supervised                                                      AE: treadmill, elliptical, cycling/rowing ergometer or combination\                                                       16.4^a^          3                           High: 50--60 AE,\                               AE: vigorous (average high: 65.2%, combined: 67.4% of VO2 peak)\
                                                                                                                                                                                                                                                                                                                                RE: four leg exercises, five upper-body exercises                                                                                                                      Combined: 50--60 (25--30 AE+30--35 RE)          RE: 60%--75% of estimated 1 RM, 2 sets of 10--12 reps

  Saxton *et al*[@R32]                 Multimodal exercise and dietary advice programme                                                                                                  UC                                                             AE, RE, supervised                                                      AE: treadmill, cross-trainer, cycling/rowing ergometer\                                                                   24               3                           45:30AE+10--15 RE                               AE: 65%--85% max HR (220-age) bpm
                                                                                                                                                                                                                                                                                                                                RE: resistance bands, hand weights, stability balls                                                                                                                                                                    

  Steindorf *et al*[@R30]              Progressive resistance training                                                                                                                   Muscle relaxation                                              RE, supervised, group                                                   Machine-based resistance exercises, three leg exercises,\                                                                 12               2                           60                                              60%--80% of 1 RM 1--3 sets of 8--12 repetitions\
                                                                                                                                                                                                                                                                                                                                five upper body exercises                                                                                                                                                                                              (ACSM rec)

  Rock *et al*[@R6]                    Intensive exercise and weight loss programme                                                                                                      Written material on exercise and diet                          Unsupervised and home based                                             NR                                                                                                                        52               NR                          150/week                                        Moderate (ACSM rec)

  Schmidt *et al*[@R41]                Progressive resistance training                                                                                                                   Muscle relaxation                                              RE, supervised                                                          Machine-based resistance exercises, three leg exercises, five upper body exercises                                        12               2                           60                                              60%--80% of 1 RM 1--3 sets of 8--12 repetitions\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       (ACSM rec)

  Travier *et al*[@R37]                Individualised exercise programme                                                                                                                 UC                                                             AE, RE, supervised                                                      AE: interval training, mode NR\                                                                                           18               2                           60:5 warm up,\                                  AE: Alternating at (3×2 min to 2×7 min) or below (3×4 min decreasing to 1×7 min) ventilatory threshold HR\
                                                                                                                                                                                                                                                                                                                                RE: arms, legs, shoulder, trunk exercises, mode NR                                                                                                                     25 AE+RE,\                                      RE: 45%--75% of 1 RM, 1--2 sets of 10--20 repetitions
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       5 cool down                                     

  Gokal *et al*[@R40]                  Self-managed progressive programme                                                                                                                UC                                                             AE, home based                                                          Walking                                                                                                                   12               3                           30                                              Moderate (Department of Health, Physical Activity, Health Improvement and\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Prevention rec, 2004)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACS, American Cancer Society; ACSM, American College of Sports Medicine; AE, Aerobic; AHA, American Heart Association; BRPES, Borg Rating Perceived Exertion Scale; RE, Resistance; RM, Repetition Maximum; UC, Usual Care.

Effects of exercise interventions on depressive symptoms {#s3e}
--------------------------------------------------------

Based on the fourteen reviewed randomised control trials, which included 1701 participants in total, we found that reduction in depressive symptoms showed a small to moderate effect in depressive symptoms in favour of the exercise ([figure 2](#F2){ref-type="fig"}), g=−0.38 (95% CI −0.89 to 0.13, P=0.14). The heterogeneity between studies was moderate (χ^2^=57.24, df=13, P\<0.00001; I^2^=77%) ([figure 3](#F3){ref-type="fig"}).

![Funnel plot of SE by Hedges' g. MD, mean difference.](esmoopen-2017-000271f02){#F2}

![Forest plot of effect sizes gauging impact of exercise on depression.](esmoopen-2017-000271f03){#F3}

Effects from the type of exercise interventions on depressive symptoms {#s3f}
----------------------------------------------------------------------

### Aerobic exercise interventions {#s3f1}

With regard to the type of the exercise intervention, aerobic interventions yielded a large and significant effect on depression at the last follow-up measurement compared with the control groups ([figure 4](#F4){ref-type="fig"}), g=−1.23 (95% CI −1.97 to --0.49, P=0.001). There was no substantial heterogeneity (χ^2^=1.43, df=2, P=0.49; I^2^=0%). The mean length of these interventions was 12.66±3 weeks, 120 min of moderate aerobic exercise per week.

![Forest plot of effect sizes gauging impact of the aerobic exercise on depression.](esmoopen-2017-000271f04){#F4}

### Resistance exercise interventions {#s3f2}

In addition, the resistance exercise interventions yielded a small and less significant effect in favour of the exercise group, g=−0.37 (95% CI −4.15 to 3.41, P=0.85). There was no substantial heterogeneity (χ^2^=0.03, df=1, P=0.86; I^2^=0%). The mean length of these interventions was 12 weeks, 120 min of moderate resistance exercise per week.

### Aerobic and resistance exercise interventions {#s3f3}

The six aerobic and resistance exercise interventions yielded a moderate effect in favour of exercise, g=−0.79 (95% CI −1.64 to 0.07, P=0.07). The heterogeneity was moderate (χ^2^=17.82, df=5, P=0.003; I^2^=72%) ([figure 5](#F5){ref-type="fig"}). The mean length of these interventions was 13±6 weeks, 165 min of moderate aerobic and resistance exercise per week.

![Forest plot of effect sizes gauging impact of the aerobic and resistance exercise on depression.](esmoopen-2017-000271f05){#F5}

### Yoga exercise interventions {#s3f4}

The two yoga supervised interventions showed no statistically significant differences in depression compared with the control group, g=1.31 (95% CI −1.85 to 4.47, P=0.42). There was no substantial heterogeneity (χ^2^=0.66, df=1, P=0.42; I^2^=0%). The mean length of these interventions was 9±3 weeks, 180 min of low yoga exercise per week.

Effects from the duration of exercise interventions on depressive symptoms {#s3g}
--------------------------------------------------------------------------

### Exercise duration: up to 12 weeks {#s3g1}

Exercise duration up to 12 weeks yielded a moderate to large effect, g=−1.69 (95% CI −2.66 to −0.73, P=0.0006). The heterogeneity was low (χ^2^=13.32, df=9, P=0.15; I^2^=32%) ([figure 6](#F6){ref-type="fig"}).

![Forest plot of exercise programme.](esmoopen-2017-000271f06){#F6}

### Exercise duration: over 12 weeks {#s3g2}

Exercise duration over 12 weeks yielded a small and less significant effect, g=−0.13 (95% CI −0.47 to 0.73, P=0.68). The heterogeneity was high (χ^2^=34.10, df=3, P≤0.00001; I^2^=91%).

Effects from the weekly duration of exercise interventions on depressive symptoms {#s3h}
---------------------------------------------------------------------------------

### Exercise duration: ≤**135** min/week {#s3h1}

Exercise duration within a week period (≤135 min/week) yielded a moderate to large effect, g=−0.82 (95% CI −1.54 to −0.10, P=0.16). The heterogeneity was low (χ^2^=9.17, df=6, P=0.03; I^2^=35%) ([figure 7](#F7){ref-type="fig"}).

![Forest plot of exercise programme.](esmoopen-2017-000271f07){#F7}

### Exercise duration: ≥**135** min/week {#s3h2}

Exercise duration within a week period (≥135 min/week) yielded no significant effect, g=0.06 (95% CI −0.67 to 0.78, P=0.88). The heterogeneity was high (χ^2^=45.26, df=6, P≤0.00001; I^2^=87%).

Effects from exercise interventions on depressive symptoms in patients under treatment and post-treatment {#s3i}
---------------------------------------------------------------------------------------------------------

### Exercise interventions in patients under treatment {#s3i1}

Exercise interventions in patients under treatment yielded a moderate effect, g=−0.54 (95% CI −1.16 to 0.08, P=0.09). The heterogeneity was low (χ^2^=6.69, df=5, P=0.24; I^2^=25%) ([figure 8](#F8){ref-type="fig"}).

![Forest plot of exercise during treatment.](esmoopen-2017-000271f08){#F8}

### Exercise interventions in patients post-treatment {#s3i2}

Exercise interventions in patients post-treatment yielded a small and less significant effect, g=−0.05 (95% CI −0.95 to 0.85, P=0.91). The heterogeneity was high (χ^2^=49.79, df=7, P≤0.00001; I^2^=86%).

Discussion {#s4}
==========

In this literature review, we used studies published in the last years in order to assess the effects of physical activity and exercise interventions on depressive symptoms in breast cancer survivors during and after treatment. Additionally, we tried to identify the optimal exercise frequency and duration for the decrease of depressive symptoms. The main analysis indicates that exercise has a small to moderate effect (g=−0.38) on depression mood compared with the control groups. The I^2^ test showed a moderate heterogeneity, I^2^=77%, and the results from the methods of Begg and Egger *et al* yielded no evidence of publication bias. This indicates that exercise is beneficial to breast cancer survivors compared with inactivity. Over half of the survivors that are having depressive symptoms globally do not receive any treatment at all, and exercise and physical activity may make them feel better and more useful.[@R43] These findings are similar with results from other studies,[@R7] although the overall magnitude of reduction in depressive symptoms in the current one (g=−0.38) is approximately 50% greater. Moreover, the analysis showed a moderate effect (g=−0.54) for patients who are under treatment. It might be worth offering exercise interventions in breast cancer survivors starting as early as possible after diagnosis in order to decrease depressive symptoms.

Although the majority of participants in the reviewed studies scored within normal level range of depressive symptoms at baseline, it is important to be referred that exercise interventions had significant positive effects on women with mild or clinical levels of depressive symptoms at baseline and those women under treatment.[@R39] This finding may help physicians and care practices for future research. Other studies have examined the role of exercise in breast cancer survivors under cancer treatment but, due to their moderate methodological quality, no safe conclusions can be drawn.[@R44] On the other hand, improvements in depressive symptoms and depression mood resulted from exercise interventions were also recorded in a meta-analysis of 17 randomised controlled trials involving 748 breast cancer survivors undergoing chemotherapy and/or radiotherapy, but further investigation needs to be done.[@R16] Even during treatment (ie, chemotherapy), women need to be motivated to participate in both aerobic or aerobic and resistance training programmes of moderate intensity, with standard doses of aerobic interventions being more beneficial to women with clinical levels of depressive symptoms at baseline.[@R39] These findings suggest that exercise is capable to reduce depressive symptoms and is tolerant, feasible and well accepted by people under or after treatment. These results are similar with other studies in the literature that support the beneficial role of exercise.[@R46]

Regarding exercise intervention characteristics, in terms of type, the present analyses showed significantly beneficial effects of moderate aerobic exercise, g=−1.23. According to the ACS guidelines, in order to prevent cancer, adults should be engaged in at least 150 min of moderate aerobic exercise programmes.[@R47] Continuous aerobic exercise training increases the levels of nor-adrenaline, epinephrine, serotonine and β-endorphine hormones, which are responsible for depressive symptoms.[@R48]

Resistance exercise interventions yielded a small and no significant effect on depressive symptoms, g=−0.37, but due to the small number of studies included in this analysis, these findings should be interpreted with caution. In the same wavelength, ACS makes no recommendation of resistance training among cancer survivors.[@R47] On the other hand, ACSM suggests at least 2 days per week of resistance training exercise in order to achieve health benefits from exercise interventions.[@R50]

Aerobic and resistance training interventions yielded a moderate effect in favour of exercise, g=−0.79. This means that exercise programmes have to be applied with regard to breast cancer survivors' specific characteristics and intensities. A combination of aerobic and resistance training programmes have to be adapted to their individual needs and physical abilities especially during or after cancer treatment.[@R52]

Finally, yoga exercise interventions yielded no statistically significant differences in depression compared with the control group. This is in contradiction with other studies, which showed beneficial results on depression from *asanas* yoga programme.[@R57] The different programmes of yoga intervention (ie, postures or exercise as standing, sun salutation, balance) might be an explanation for that. The current literature analysis included a small number of yoga studies; thus, these findings should be interpreted with caution.

Regarding the duration (minutes and weeks), our results showed significant effects for ≥135 min per week, g=−0.82 (ideal divided equally), for up to 12 weeks, g=−1.69. Our study also showed that less than 150 min per week are needed in order to decrease depressive symptoms among breast cancer survivors.

The findings from the current study showed that exercise is a significant alternative way to decrease depressive symptoms among breast cancer survivors, even those under treatment, with moderate aerobic exercise interventions being most effective than other interventions with duration up to 135 min per week for up to 12 weeks. The high retention and adherence rates reported in most studies in conjunction with the recording of minimum adverse events related to exercise are encouraging in terms of feasibility and safety of exercise interventions. From clinical practice, it might be worth offering exercise interventions starting as early as possible after diagnosis to help survivors.

Limitations and future research {#s5}
===============================

Limitations of the presented studies include the mostly small sample sizes (less than 100 participants), the recruiting of volunteers and the homogeneity of participants regarding race and socioeconomic status. More specifically, the majority of women in all studies were white, well educated and employed, and consequently, patients from minorities and subpopulations, who are more susceptible to depressive symptoms and thus in major need of effective treatments, have been under-represented. As for limitations of the present literature review, we must note that depressive symptoms were identified as the secondary outcome in the majority of the studies. Furthermore, the inclusion of studies with different measurement tools for depression might have led to comparison of different definitions of symptoms of depression. Finally, an analysis of the exercise intensity was not possible given that the 11 out of 14 included studies used moderate intensity in their exercise protocols.

Despite those limitations, we provide concrete evidence that exercise is associated with beneficial outcomes in breast cancer survivors. Future studies should seek to recruit depressed cancer survivors regardless of their willingness to participate in exercise interventions at first, by screening all potential participants and subsequently offering advice through physicians and oncology healthcare professionals about the biological and psychological positive effects of exercise during and after breast cancer treatment. Accordingly, large randomised controlled trials should include diverse ethnic and minority groups as well as other subgroups of breast cancer survivors, such as younger women and women who are of a lower level of education or unemployed, in order to identify those who will mostly benefit regarding depressive symptoms from exercise intervention.

Conclusions {#s6}
===========

Depressive symptoms and depressive mood are a major psychosocial side effect of breast cancer diagnosis and treatment and are associated with poor adherence to treatment plan and reduced survival rates. Thus, effective treatments are of outmost importance. Engaging in regular physical activity is known to improve physical fitness and psychosocial well-being of breast cancer survivors. Regarding depression mood, exercise has been viewed as a cost-effective and non-invasive treatment alternative.

In the present literature analyses, we confirmed that exercise provides a small to moderate reduction in depression mood among breast cancer survivors. The average of ≥135 min per week for up to 12 weeks of supervised, moderate, aerobic exercise is more beneficial for depressive symptoms for patients under or after treatment. It is possible due to difficulty handling the burden of the disease, that women who suffer from depressive symptoms either precancer or due to cancer diagnosis are not willing to participate in exercise interventions. Cancer survivors should try to avoid inactivity. Physicians and medical care providers should suggest physical activity in order to optimise physical and psychological symptoms that are related to breast cancer. Nevertheless, exercise can be safely recommended to women with mild or clinical levels of depressive symptoms as there are no negative side effects of exercise participation throughout the course of cancer survivorship.
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